Annual report
Annual Report 2026
Source: Nse
Ajooni Biotech Limited (AJOONI)
Small CapPharma stocks · Small cap · NSE
Ajooni Biotech Limited operates in Animal Health, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals04 Oct 2026 · screener
Latest result16 Aug, 01:12 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
54Neutralfull bear SMA stack · SMA20 -14.3% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 24
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
AJOONID candles · FIT view-31.5%Latest close ₹2.92 on 2026-10-19
Bar
-3.3%
RSI
34
MACD hist
0.01
52W pos
9%
2026-10-19O ₹3.02H ₹3.04L ₹2.76C ₹2.92Vol 2.1L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
AJOONINifty PharmaNifty 500
- AJOONI
- -30.5%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -24.9 pp
Chart stats
19 Oct 2026- From 52W high
- -46.9%
- 52W range position
- 9%
- ATR (14)
- 5.2%
- Volume vs 20D
- 0.65x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹2.7 - ₹3.3
₹5.5
₹2.7 - ₹5.5
₹0.2
Latest completed session
20-session average
36.3% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE56
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +103.0% · PAT -44.9% YoY
Technical
Neutral54
Price trend and sector-relative-strength timing.
Valuation
Legacy model+71.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence62
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -45% YoY · margin compression · Rev +103% YoY
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹63.5 Cr | +103.0% | +4.7% |
| EBITDA | ₹1.7 Cr | +135.2% | +65.3% |
| Operating margin | 2.6% | +36 bps | +96 bps |
| PAT | ₹0.4 Cr | -44.9% | -54.7% |
| PAT margin | 0.7% | -181 bps | -89 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 13.50
- P/B
- 0.59
- EV/EBITDA
- 7.14
- Market Cap
- 53.40Cr
Profitability
- ROE
- 4.28%
- ROCE
- 6.11%
- ROA
- 3.33%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 29.00%
- EPS 5Y
- 60.00%
- Revenue 3Y
- 35.00%
- EPS 3Y
- 51.00%
Balance Sheet
- Debt/Equity
- 0.20
- Interest Coverage
- 7.00×
- Altman Z
- 4.03
- Book Value
- 5.29
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- -6.00 Cr
- EPS TTM
- 0.23
Shareholding
- Promoter Hold
- 30.53%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 3%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 182+58.3% vs prev
Net Profit
₹ CrLatest: 4.0+33.3% vs prev
Return on Equity
%Latest: 4.4+29.0% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 34. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~16.7% over last month) — short-term momentum negative.
- RSI(14) at 34 — rising, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 47% off 52W high · 9% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
8
RS percentile
Stage 4 Downtrend
1M return
-11.0%
3M return
-30.5%
6M return
-32.3%
1Y return
-43.6%
RS 1D
-1
RS 20D
-3
Sector rank
#1
Industry rank
#65
Stage evidence
- Price is 23.9% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -4.3%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
improving
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 57.05-2.31%
RS vs Nifty 50057
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · FAIR VALUEValuation28/30
Growth21/25
Quality0/20
Balance Sheet10/15
Cash Flow1/10
Piotroski
5/9 (+3)
Penalties
-7
Raw sum
56
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
56/100 · legacy band FAIR VALUE
Positive drivers
- Fair-value margin of safety is positive at 71.8%.
- Valuation contributes 28/30 to the score.
- Growth contributes 21/25 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
13.5
PB
0.6
EV/EBITDA
7.1
ROE
4.3%
ROCE
6.1%
FCF Yield
—
Debt/Equity
0.2
MoS
+71.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
56
Previous: 56
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+71.8%
Previous: +71.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
56
56
56
56
56
53
56
56
56
56
56
56
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹5.23
+44.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹10.35
+71.8% MoS
PEG
0.24
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
HESTERBIO
Small
Hester Biosciences Limited
Biotechnology
match 150
57
33.7
15.9%
+28%
FAIR VALUE
INDOUS
Small
Indo Us Biotech Limited
Biotechnology
match 125
42
29.9
16.9%
+43%
WATCHLIST
SHEEL
SME
Sheel Biotech Ltd.
Biotechnology
match 121
60
10.4
11.2%
+76%
UNDERVALUED
NATHBIOGEN
Small
Nath Bio-Genes (India) Limited
Biotechnology
match 120
35
7.7
5.3%
-124%
WATCHLIST
BIOCON
Mid
Biocon Limited
Biotechnology
match 114
32
78.9
1.4%
-2833%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Ajooni Biotech Limited operates in Animal Health, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
62Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 35th percentile of the scored universe and 24th percentile within Pharma. Main check: cash conversion is weak at 40/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
6 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
35th percentile
overall median 67 · Pharma: 24th pctile, median 70 · Small: 40th pctile, median 66
Evidence depth
Financial-only
6 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
40
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
48
watch · capital discipline
Results
61
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸OPM spread across recent quarters is 3.5%.
Trust risks
- ▸Operating cash flow is negative at ₹-6 Cr.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 6.5%.
- ▸ROE is low at 4.8%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Ajooni Biotech Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2025
Source: Nse
Investor presentationSep 2024
Sep 2024 · Investor presentation · Ajooni Biotech Limited has informed the Exchange regarding 'Investor Presentation'.
Source: Nse
Investor presentationOct 2024
Oct 2024 · PPT
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.